These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 5134859)

  • 1. [Protective effect of the domestic oil adjuvant vaccine against influenza (1 year after vaccination)].
    Bervar M; Papo I; Piscević S; Duknić M
    Vojnosanit Pregl; 1971 Oct; 28(10):505-11. PubMed ID: 5134859
    [No Abstract]   [Full Text] [Related]  

  • 2. Experience in the United Kingdom with oil adjuvant influenza vaccines.
    Perkins FT
    Ann Allergy; 1972 May; 30(5):288-91. PubMed ID: 5063341
    [No Abstract]   [Full Text] [Related]  

  • 3. Freund's complete and incomplete adjuvants, preparation, and quality control standards for experimental laboratory animals use.
    Stewart-Tull DE
    Methods Mol Biol; 2010; 626():59-72. PubMed ID: 20099121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New metabolizable immunologic adjuvant for human use. 5. Evaluation of highly purified influenza-virus vaccine in adjuvant 65.
    Weibel RE; Woodhour AF; Stokes J; Metzgar DP; Hilleman MR
    N Engl J Med; 1967 Jan; 276(2):78-84. PubMed ID: 6015520
    [No Abstract]   [Full Text] [Related]  

  • 5. A proposal for safety standards for human use of cholera toxin (or Escherichia coli heat-labile enterotoxin) derivatives as an adjuvant of nasal inactivated influenza vaccine.
    Tamura SI; Kurata T
    Jpn J Infect Dis; 2000 Jun; 53(3):98-106. PubMed ID: 10957706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.
    Khurana S; Chearwae W; Castellino F; Manischewitz J; King LR; Honorkiewicz A; Rock MT; Edwards KM; Del Giudice G; Rappuoli R; Golding H
    Sci Transl Med; 2010 Jan; 2(15):15ra5. PubMed ID: 20371470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Technology transfer of an oil-in-water vaccine-adjuvant for strengthening pandemic influenza preparedness in Indonesia.
    Ventura R; Brunner L; Heriyanto B; de Boer O; O'Hara M; Huynh C; Suhardono M; Collin N
    Vaccine; 2013 Mar; 31(12):1641-5. PubMed ID: 22884665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Innovation of vaccine adjuvants].
    Shimizu Y; Karamatsu K; Matsubara A; Yasutomi Y
    Nihon Rinsho; 2008 Oct; 66(10):1915-21. PubMed ID: 18939490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Problems of specific cellular immunity against influenza].
    Shvartsman IaS; Ispolatova AV; Tsybul'skaia NV
    Usp Sovrem Biol; 1979; 88(1):77-92. PubMed ID: 388905
    [No Abstract]   [Full Text] [Related]  

  • 10. [Introduction to novel vaccine adjuvants and their role in influenza vaccination].
    Haensler J
    Ann Pharm Fr; 2013 Mar; 71(2):104-8. PubMed ID: 23537411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Increase of immune response by administration of metabolizable vegetable oil emulsions].
    Audibert F; Chedid L
    C R Acad Hebd Seances Acad Sci D; 1975 Apr; 280(13):1629-32. PubMed ID: 811378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies for safety of adjuvant 65.
    Hilleman MR; Woodhour AF; Friedman A; Phelps AH
    Ann Allergy; 1972 Aug; 30(8):477-83. PubMed ID: 5044500
    [No Abstract]   [Full Text] [Related]  

  • 13. Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania.
    Fox CB; Huynh C; O'Hara MK; Onu A
    Vaccine; 2013 Mar; 31(12):1633-40. PubMed ID: 23103197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine.
    Song JY; Cheong HJ; Noh JY; Seo YB; Choi WS; Cho GJ; Hwang TG; Kim WJ
    J Med Virol; 2013 Sep; 85(9):1591-7. PubMed ID: 23852684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influenza infection in human host: challenges in making a better influenza vaccine.
    Virk RK; Gunalan V; Tambyah PA
    Expert Rev Anti Infect Ther; 2016; 14(4):365-75. PubMed ID: 26885890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoimmunity induced by adjuvant hydrocarbon oil components of vaccine.
    Kuroda Y; Nacionales DC; Akaogi J; Reeves WH; Satoh M
    Biomed Pharmacother; 2004 Jun; 58(5):325-37. PubMed ID: 15194169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The protective effect of polyvalent oil-adjuvant influenza vaccine in chdren.
    Quilligan JJ; Baernstein HD
    Pediatrics; 1966 Aug; 38(2):207-10. PubMed ID: 5944155
    [No Abstract]   [Full Text] [Related]  

  • 18. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
    Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The roles of early alert and of adjuvant in the control of Hong Kong influenza by vaccines.
    Hilleman MR
    Bull World Health Organ; 1969; 41(3):623-8. PubMed ID: 4985377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A serological comparison of Pasteurella haemolytica vaccines containing different adjuvants.
    Wells PW; Gilmour NJ; Burrells C; Thompson DA
    Res Vet Sci; 1979 Sep; 27(2):248-50. PubMed ID: 523817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.